Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Is high-dose chemotherapy effective in patients with relapsed or refractory germ cell tumors?

Nature Clinical Practice Urology volume 5, pages 78–79 (2008)Cite this article

boxed-textEinhorn LH et al. (2007) High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med 357: 340–348

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Sonpavde G et al. (2007) Management of recurrent testicular germ cell tumors. Oncologist 12: 51–61

    Article  Google Scholar 

  2. Ronnen EA et al. (2005) Incidence of late-relapse germ cell tumor and outcome to salvage chemotherapy. J Clin Oncol 23: 6999–7004

    Article  Google Scholar 

  3. Kondagunta GV et al. (2005) Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol 23: 6549–6555

    Article  CAS  Google Scholar 

  4. Beyer J et al. (1996) High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. J Clin Oncol 14: 2638–2645

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Mandy Aujla, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. DR Feldman is a Fellow at the Division of Medical Oncology and Hematology, Department of Medicine, Division of Solid Tumor Oncology, RJ Motzer is an Attending Physician at the Genitourinary Oncology Service, and DF Bajorin is Program Director for the Fellowship in Medical Oncology and Hematology program, and Director of the Clinical Research Curriculum for training clinical investigators, at Memorial Sloan–Kettering Cancer Center, New York, NY, USA.,

    Darren R Feldman, Robert J Motzer & Dean F Bajorin

  2. RJ Motzer and DF Bajorin are also Professors of Medicine at Weill Medical College of Cornell University, New York, NY, USA.,

    Robert J Motzer & Dean F Bajorin

Authors
  1. Darren R Feldman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert J Motzer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dean F Bajorin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dean F Bajorin.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Feldman, D., Motzer, R. & Bajorin, D. Is high-dose chemotherapy effective in patients with relapsed or refractory germ cell tumors?. Nat Rev Urol 5, 78–79 (2008). https://doi.org/10.1038/ncpuro0999

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpuro0999

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing